Sharp Ash (603168.SH): Net profit of 4.296,600 yuan in the first quarter decreased by 80.93% year-on-year

On April 29, GLONGHUI (603168.SH) released its first quarter report. Operating revenue was 138 million yuan, down 15.02% year on year, net profit of 4.296,600 yuan, down 80.93% year on year, after deducting non-net profit of 4.359 million yuan, down 82.06% year on year, with basic earnings of 0.01 yuan per share.

Gelonghui FinanceApr 29 16:00

Investors Can Find Comfort In Zhejiang Shapuaisi PharmaceuticalLtd's (SHSE:603168) Earnings Quality

Shareholders appeared unconcerned with Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.'s (SHSE:603168) lackluster earnings report last week. We think that the softer headline numbers might be getting coun

Simply Wall StApr 27 06:39

Express News | Sharp Ace: Obtaining Approval Notice for Drug Supplement Application for Sodium Acetate Ringer Injection

BreakingsApr 24 16:59

Express News | Sharp Ace: R&D investment increased 53.06% year-on-year in 2023

BreakingsApr 21 02:45

Sharp Ash (603168.SH) announced its 2023 annual results, net profit of 25.41 million yuan, a year-on-year decrease of 43.23%

Zhitong Finance App News, according to the 2023 Annual Report. The company achieved revenue of 645 million yuan in 2023, an increase of 17.37% over the previous year; net profit to mother of 25.41 million yuan, a year-on-year decrease of 43.23%; after deducting loss of 4.01 million yuan in non-net profit, which changed from profit to loss over the previous year; basic earnings per share were 0.07 yuan. 603168.SH The company plans to pay a cash dividend of 0.21 yuan (tax included) for every 10 shares. During the reporting period, the company achieved operating income of 644.9702 million yuan, an increase of 954.3332 million yuan over the same period last year, an increase of 17.37% over the same period last year, mainly

Zhitong FinanceApr 19 21:49

Shapuaisi Pharma Gets China's Nod to Market Sodium Hyaluronate Eye Drops

Zhejiang Shapuaisi Pharmaceutical (SHA:603168) obtained marketing approval from China's medical products administrator for its sodium hyaluronate eye drops, according to a Wednesday filing with the Sh

MT NewswiresApr 17 17:03